Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 12 on this page, newest registry updates first. Search checked 2026-11-09 10:31 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Not applicableCompletedINTERVENTIONAL

Near Normalisation of BG Improves the Potentiating Effect of GLP-1

ClinicalTrials.gov · NCT00612625 · Registry updated: 2008-02-12

Condition / research focus: Diabetes Mellitus Type 2
Sponsor: Hvidovre University Hospital
Countries with listed sites: Denmark
Registry dates and results: Start: 2004-02. Completion: 2004-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

glucagon-like peptide-1 (drug)
Saline (drug)

Where the study takes place — 1 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Dept. of Endocrinology, Hvidovre Hospital
Copenhagen, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Beta-Cell Function After Near-Normalisation of Blood Glucose

ClinicalTrials.gov · NCT00612950 · Registry updated: 2008-02-12

Condition / research focus: Type 2 Diabetes
Sponsor: Hvidovre University Hospital
Countries with listed sites: Denmark
Registry dates and results: Start: 2006-10. Completion: 2007-05 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

glucagon-like peptide-1, (drug)
glucose dependent insulinotropic polypeptide (drug)
Saline (drug)

Where the study takes place — 1 listed sites

Dept. of Endocrinology, Hvidovre Hospital
Copenhagen, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Effect of 48 Hours of Treatment With the Natural Peptide-Hormone GLP-1 in Patients With Chronic Heart Failure

ClinicalTrials.gov · NCT00264199 · Registry updated: 2007-12-27

Condition / research focus: Heart Failure, Congestive
Sponsor: Aarhus University Hospital Skejby
Countries with listed sites: Denmark
Registry dates and results: Start: 2005-12. Completion: 2007-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-1 (drug)
placebo (drug)

Where the study takes place — 1 listed sites

Afdeling B, Skejby Hospital
Aarhus, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men

ClinicalTrials.gov · NCT00256256 · Registry updated: 2007-10-30

Condition / research focus: Type 2 Diabetes; Stroke; Myocardial Infarction
Sponsor: University of Aarhus
Countries with listed sites: Denmark
Registry dates and results: Start: 2005-11. Completion: 2007-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

glucagon-like-peptide-1 (drug)

Where the study takes place — 1 listed sites

Department of pharmacology, Aarhus university
Aarhus, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2

ClinicalTrials.gov · NCT00473733 · Registry updated: 2007-05-15

Condition / research focus: Diabetes Mellitus Type 2
Sponsor: Assaf-Harofeh Medical Center
Countries with listed sites: Israel
Registry dates and results: Start: Not reported. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP receptors expression (procedure)
ESOPHAGOGASTRODUODENOSCOPY (procedure)

Where the study takes place — 1 listed sites

Assaf Harofeh Medical Center
Tsrifin, Israel
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Insulin NovoRapid Versus Actrapid in Treatment of Type 1 Diabetic Patients During Daily Adjustment of Insulin Dose

ClinicalTrials.gov · NCT00145353 · Registry updated: 2006-10-11

Condition / research focus: Type 1 Diabetes Mellitus
Sponsor: Odense University Hospital
Countries with listed sites: Denmark
Registry dates and results: Start: 2004-11. Completion: 2006-06 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Insulin NovoRapid versus Actrapid (drug)

Where the study takes place — 1 listed sites

Diabetes Research Center
Odense, Funen, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

The Importance of Glucagon-Like Peptide-2 (GLP-2)in Mesenteric Bloodflow in Humans

ClinicalTrials.gov · NCT00273000 · Registry updated: 2006-09-11

Condition / research focus: Healthy
Sponsor: Glostrup University Hospital, Copenhagen
Countries with listed sites: Denmark
Registry dates and results: Start: 2006-01. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-2 (drug)

Where the study takes place — 1 listed sites

Rigshospitalet
Copenhagen, Copenhagen City, Denmark
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Very Low Dose-Glucagon in Subjects With Type 1 Diabetes Mellitus

ClinicalTrials.gov · NCT00304538 · Registry updated: 2006-08-23

Condition / research focus: Type 1 Diabetes
Sponsor: DiObex
Countries with listed sites: United States
Registry dates and results: Start: 2006-03. Completion: 2006-07 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

very low dose (VLD) glucagon (drug)

Where the study takes place — 1 listed sites

University Of California, San Diego
San Diego, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Acute Metabolic Effects of LAF 237 in Type 2 Diabetics

ClinicalTrials.gov · NCT00230464 · Registry updated: 2006-01-04

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: The University of Texas Health Science Center at San Antonio
Countries with listed sites: United States
Registry dates and results: Start: 2004-11. Completion: 2005-09 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

LAF 237 (drug)

Where the study takes place — 1 listed sites

Audie L Murphy VA Hospital
San Antonio, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography

ClinicalTrials.gov · NCT00155376 · Registry updated: 2005-11-28

Condition / research focus: Liver Disease
Sponsor: National Taiwan University Hospital
Countries with listed sites: Taiwan
Registry dates and results: Start: 2005-09. Completion: 2005-09 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

morphine and glucagon (drug)

Where the study takes place — 1 listed sites

National Taiwan University Hospital
Taipei, Province of Taiwan, Taiwan
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion

ClinicalTrials.gov · NCT00005889 · Registry updated: 2005-06-24

Condition / research focus: Infant, Low Birth Weight; Hyperglycemia
Sponsor: National Center for Research Resources (NCRR)
Countries with listed sites: United States
Registry dates and results: Start: 1999-10. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (10)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

alanine (drug)
amino acids (drug)
glucagon (drug)
glucose (drug)
glutamine (drug)
glycerol (drug)
insulin (drug)
leucine (drug)
lipids (drug)
urea (drug)

Where the study takes place — 1 listed sites

Baylor College of Medicine
Houston, Texas, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

NNC 90-1170 Mechanism of Action: A Double-Blind, Randomized, Single-Center, Placebo-Controlled, Crossover Study to Examine Beta-Cell Responsiveness to Graded Glucose Infusion in Subjects With Type 2 Diabetes

ClinicalTrials.gov · NCT00013910 · Registry updated: 2005-06-24

Condition / research focus: Diabetes Mellitus, Non-Insulin-Dependent
Sponsor: National Center for Research Resources (NCRR)
Countries with listed sites: United States
Registry dates and results: Start: Not reported. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

NNC 90-1170 (drug)

Where the study takes place — 1 listed sites

University of Michigan
Ann Arbor, Michigan, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 12 on this page, newest registry updates first. Search checked 2026-11-09 10:31 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Not applicableCompletedINTERVENTIONAL

Near Normalisation of BG Improves the Potentiating Effect of GLP-1

ClinicalTrials.gov · NCT00612625 · Registry updated: 2008-02-12

Condition / research focus: Diabetes Mellitus Type 2
Sponsor: Hvidovre University Hospital
Countries with listed sites: Denmark
Registry dates and results: Start: 2004-02. Completion: 2004-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

glucagon-like peptide-1 (drug)
Saline (drug)

Where the study takes place — 1 listed sites

Dept. of Endocrinology, Hvidovre Hospital
Copenhagen, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Beta-Cell Function After Near-Normalisation of Blood Glucose

ClinicalTrials.gov · NCT00612950 · Registry updated: 2008-02-12

Condition / research focus: Type 2 Diabetes
Sponsor: Hvidovre University Hospital
Countries with listed sites: Denmark
Registry dates and results: Start: 2006-10. Completion: 2007-05 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

glucagon-like peptide-1, (drug)
glucose dependent insulinotropic polypeptide (drug)
Saline (drug)

Where the study takes place — 1 listed sites

Dept. of Endocrinology, Hvidovre Hospital
Copenhagen, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Effect of 48 Hours of Treatment With the Natural Peptide-Hormone GLP-1 in Patients With Chronic Heart Failure

ClinicalTrials.gov · NCT00264199 · Registry updated: 2007-12-27

Condition / research focus: Heart Failure, Congestive
Sponsor: Aarhus University Hospital Skejby
Countries with listed sites: Denmark
Registry dates and results: Start: 2005-12. Completion: 2007-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-1 (drug)
placebo (drug)

Where the study takes place — 1 listed sites

Afdeling B, Skejby Hospital
Aarhus, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men

ClinicalTrials.gov · NCT00256256 · Registry updated: 2007-10-30

Condition / research focus: Type 2 Diabetes; Stroke; Myocardial Infarction
Sponsor: University of Aarhus
Countries with listed sites: Denmark
Registry dates and results: Start: 2005-11. Completion: 2007-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

glucagon-like-peptide-1 (drug)

Where the study takes place — 1 listed sites

Department of pharmacology, Aarhus university
Aarhus, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2

ClinicalTrials.gov · NCT00473733 · Registry updated: 2007-05-15

Condition / research focus: Diabetes Mellitus Type 2
Sponsor: Assaf-Harofeh Medical Center
Countries with listed sites: Israel
Registry dates and results: Start: Not reported. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP receptors expression (procedure)
ESOPHAGOGASTRODUODENOSCOPY (procedure)

Where the study takes place — 1 listed sites

Assaf Harofeh Medical Center
Tsrifin, Israel
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Insulin NovoRapid Versus Actrapid in Treatment of Type 1 Diabetic Patients During Daily Adjustment of Insulin Dose

ClinicalTrials.gov · NCT00145353 · Registry updated: 2006-10-11

Condition / research focus: Type 1 Diabetes Mellitus
Sponsor: Odense University Hospital
Countries with listed sites: Denmark
Registry dates and results: Start: 2004-11. Completion: 2006-06 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Insulin NovoRapid versus Actrapid (drug)

Where the study takes place — 1 listed sites

Diabetes Research Center
Odense, Funen, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

The Importance of Glucagon-Like Peptide-2 (GLP-2)in Mesenteric Bloodflow in Humans

ClinicalTrials.gov · NCT00273000 · Registry updated: 2006-09-11

Condition / research focus: Healthy
Sponsor: Glostrup University Hospital, Copenhagen
Countries with listed sites: Denmark
Registry dates and results: Start: 2006-01. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-2 (drug)

Where the study takes place — 1 listed sites

Rigshospitalet
Copenhagen, Copenhagen City, Denmark
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Very Low Dose-Glucagon in Subjects With Type 1 Diabetes Mellitus

ClinicalTrials.gov · NCT00304538 · Registry updated: 2006-08-23

Condition / research focus: Type 1 Diabetes
Sponsor: DiObex
Countries with listed sites: United States
Registry dates and results: Start: 2006-03. Completion: 2006-07 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

very low dose (VLD) glucagon (drug)

Where the study takes place — 1 listed sites

University Of California, San Diego
San Diego, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Acute Metabolic Effects of LAF 237 in Type 2 Diabetics

ClinicalTrials.gov · NCT00230464 · Registry updated: 2006-01-04

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: The University of Texas Health Science Center at San Antonio
Countries with listed sites: United States
Registry dates and results: Start: 2004-11. Completion: 2005-09 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

LAF 237 (drug)

Where the study takes place — 1 listed sites

Audie L Murphy VA Hospital
San Antonio, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography

ClinicalTrials.gov · NCT00155376 · Registry updated: 2005-11-28

Condition / research focus: Liver Disease
Sponsor: National Taiwan University Hospital
Countries with listed sites: Taiwan
Registry dates and results: Start: 2005-09. Completion: 2005-09 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

morphine and glucagon (drug)

Where the study takes place — 1 listed sites

National Taiwan University Hospital
Taipei, Province of Taiwan, Taiwan
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion

ClinicalTrials.gov · NCT00005889 · Registry updated: 2005-06-24

Condition / research focus: Infant, Low Birth Weight; Hyperglycemia
Sponsor: National Center for Research Resources (NCRR)
Countries with listed sites: United States
Registry dates and results: Start: 1999-10. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (10)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

alanine (drug)
amino acids (drug)
glucagon (drug)
glucose (drug)
glutamine (drug)
glycerol (drug)
insulin (drug)
leucine (drug)
lipids (drug)
urea (drug)

Where the study takes place — 1 listed sites

Baylor College of Medicine
Houston, Texas, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

NNC 90-1170 Mechanism of Action: A Double-Blind, Randomized, Single-Center, Placebo-Controlled, Crossover Study to Examine Beta-Cell Responsiveness to Graded Glucose Infusion in Subjects With Type 2 Diabetes

ClinicalTrials.gov · NCT00013910 · Registry updated: 2005-06-24

Condition / research focus: Diabetes Mellitus, Non-Insulin-Dependent
Sponsor: National Center for Research Resources (NCRR)
Countries with listed sites: United States
Registry dates and results: Start: Not reported. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

NNC 90-1170 (drug)

Where the study takes place — 1 listed sites

University of Michigan
Ann Arbor, Michigan, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →